AmoyDx Announces Companion Diagnostic Collaboration with AstraZeneca for ADC Drug ENHERTU®

Amoy Diagnostics: Partnered with AstraZeneca for Antibody-Drug Conjugate (ADC) Companion Diagnostics. The company’s self-developed Human 10-Gene Mutation Combined Detection Kit (Reversible Terminator Sequencing Method) will be utilized for developing companion diagnostics based on the drug ENHERTU® to identify HER2 (ERBB2) mutation-positive Non-Small Cell Lung Cancer (NSCLC) patients.